Palmitic acid ethyl esterCAS# 628-97-7 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 628-97-7 | SDF | Download SDF |
| PubChem ID | 12366 | Appearance | Colorless needle crystal |
| Formula | C18H36O2 | M.Wt | 284.48 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | ethyl hexadecanoate | ||
| SMILES | CCCCCCCCCCCCCCCC(=O)OCC | ||
| Standard InChIKey | XIRNKXNNONJFQO-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20-4-2/h3-17H2,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Palmitic acid ethyl ester Dilution Calculator
Palmitic acid ethyl ester Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.5152 mL | 17.5759 mL | 35.1519 mL | 70.3037 mL | 87.8796 mL |
| 5 mM | 0.703 mL | 3.5152 mL | 7.0304 mL | 14.0607 mL | 17.5759 mL |
| 10 mM | 0.3515 mL | 1.7576 mL | 3.5152 mL | 7.0304 mL | 8.788 mL |
| 50 mM | 0.0703 mL | 0.3515 mL | 0.703 mL | 1.4061 mL | 1.7576 mL |
| 100 mM | 0.0352 mL | 0.1758 mL | 0.3515 mL | 0.703 mL | 0.8788 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SU14813
Catalog No.:BCC1971
CAS No.:627908-92-3
- Senampeline D
Catalog No.:BCN2033
CAS No.:62787-01-3
- Senampeline A
Catalog No.:BCN2030
CAS No.:62787-00-2
- Pterophorine
Catalog No.:BCN2118
CAS No.:62786-99-6
- Epitrametol
Catalog No.:BCN7073
CAS No.:627538-65-2
- SD-208
Catalog No.:BCC1938
CAS No.:627536-09-8
- BMS-564929
Catalog No.:BCC1425
CAS No.:627530-84-1
- 4-Amino-N-methylbenzamide
Catalog No.:BCC8685
CAS No.:6274-22-2
- SKF38393 HCl
Catalog No.:BCC6526
CAS No.:62717-42-4
- Dihydrolycorine
Catalog No.:BCN2475
CAS No.:6271-21-2
- NF 449
Catalog No.:BCC7043
CAS No.:627034-85-9
- Dioctanoylglycol
Catalog No.:BCC6662
CAS No.:627-86-1
- Jolkinol A
Catalog No.:BCN3778
CAS No.:62820-11-5
- Meglumine
Catalog No.:BCC4795
CAS No.:6284-40-8
- Senampeline E
Catalog No.:BCN2032
CAS No.:71075-42-8
- 2-Amino-6-nitrobenzothiazole
Catalog No.:BCC8544
CAS No.:6285-57-0
- Senampeline B
Catalog No.:BCN2031
CAS No.:62860-52-0
- TP 003
Catalog No.:BCC6169
CAS No.:628690-75-5
- Hecubine
Catalog No.:BCN7467
CAS No.:62874-52-6
- Cefoperazone
Catalog No.:BCC3748
CAS No.:62893-19-0
- Heptanal oxime
Catalog No.:BCN2267
CAS No.:629-31-2
- Procaterol hydrochloride
Catalog No.:BCC6937
CAS No.:62929-91-3
- H-D-Pro-NH2
Catalog No.:BCC3024
CAS No.:62937-45-5
- Kuwanon A
Catalog No.:BCN2944
CAS No.:62949-77-3
Chemical Composition and Antimigraine Activity of Essential Oil of Angelicae dahuricae Radix.[Pubmed:28731365]
J Med Food. 2017 Aug;20(8):797-803.
The aim of this study was to explore the chemical composition and the effect of essential oil of Angelicae dahuricae radix on a nitroglycerin (NTG)-induced rat model of migraine. The CO2 supercritical fluid extraction method was optimized for the extraction of essential oil of A. dahuricae radix (EOAD) and its chemical composition was determined. The migraine model was established by subcutaneous injection of NTG (10 mg/kg) 1 h after the last administration of EOAD. The therapeutic effect of EOAD and its underlying mechanism were assessed by monitoring behavioral changes, levels of nitric oxide (NO) in serum and brain tissues, plasma levels of calcitonin gene-related peptide (CGRP) and endothelin (ET), and ET/NO ratio. The optimal conditions for CO2 supercritical fluid extraction of EOAD, as determined by orthogonal test [L9(3(4))], were as follows: 2 h extraction time, 20 MPa pressure, 40 degrees C temperature, and 30 mesh. The yield of EOAD was 1.8%. On gas chromatography-mass spectrometry, 45 peaks were found in EOAD, and 22 compounds were identified and quantified. The main constituents of EOAD were 1-dodecanol (13.71%), elemene (7.54%), Palmitic acid ethyl ester (7.32%), alpha-pinene (6.25%), and 1-pentadecanol (6.08%). Compared with rat migraine model controls, EOAD (35, 70, and 140 mg/kg) significantly reduced the number of head shaking, head scratching, and hind leg shooting events, decreased serum and brain NO levels, decreased plasma CGRP, and increased ET levels in rats. ET/NO ratio was elevated to 28.68 in the EOAD high-dose group. EOAD ameliorates NTG-induced migraine in rats likely by modulating the levels of vasoactive substances.
